Thrivent Financial For Lutherans Vaxcyte, Inc. Transaction History
Thrivent Financial For Lutherans
- $45.7 Billion
- Q2 2025
A detailed history of Thrivent Financial For Lutherans transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 22,389 shares of PCVX stock, worth $980,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,389Holding current value
$980,862% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$644 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$526 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$524 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$435 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$263 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.6B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...